Redoxis is a contract research organisation with a focus on preclinical drug development and efficacy evaluation in inflammatory, autoimmune and neurodegenerative disease models. The company, Based at Medicon Village, Redoxis has its roots in academic research and retains links with academia through collaboration while continuously expanding its portfolio of offered models.
Founded as an R&D spinout in 2007 and evolving into a contract research organisation in 2010, Redoxis initially had a focus on inflammatory and autoimmune disease. Over the past year, the company has expanded its reach to offer a larger range of animal models, including a new focus on degenerative disease.
Services to the life sciences industry
Redoxis provides preclinical in vivo and in vitro models, including mechanism of action (MoA) evaluation, ex vivo ranking, pharmacokinetic (PK) investigation, biomarker identification, in vivo efficacy and biomarker analyses. Services also include standardised in vivo imaging models with relevance for autoimmune diseases including rheumatoid arthritis and multiple sclerosis.
Animal models, which represent different facets of human disease, are a vital part of preclinical research and efficacy evaluation. Mouse and rat models provided by Redoxis include models of rheumatoid arthritis, multiple sclerosis, Guillain-Barré syndrome, systemic lupus erythematosus, acute inflammation models, and psoriasis and psoriatic arthritis. Recently, Redoxis has ventured into the field of neurodegenerative disorders.
“We are expanding the range of models that we offer, and adding a new focus on neurodegenerative disease,” said Francesco Bez, senior scientist, who joined the company in mid-2017. Bez brings research experience in Parkinson’s disease, along with experience in inflammation.
“Inflammation plays an important role in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Therefore, by looking at these diseases we are retaining our focus on inflammation, but moving into the brain,” added Bez.
The company is soon to launch Parkinson’s disease models. These will include models mediated by the use of toxins, and AAV vectors, as well as transgenic Parkinson’s disease mice that mimic the disease symptoms by overexpressing alpha synuclein protein.
“We can create and tailor these models according to our client’s needs,” said Dr. Bez.
Tailored research models
Redoxis has a portfolio of standard models, but can also find solutions for specific customer requests.
“People come to us with a drug for preclinical evaluations and in collaboration we can create a new model or adjust an existing one,” said Bez. “This is particularly important for companies that need flexibility. We provide fast and solid results and custom-made studies that bring value to our customer’s preclinical programs.”
